SIRT1 and metabolic dysfunction-associated steatotic liver disease: Another study established that inhibiting miR-122 safeguards hepatocytes from lipid metabolic disorders such as NAFLD and curbs lipogenesis by elevating Sirt1 and activating the AMPK pathway (38).